IPCA Laboratories share news and announcements
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,953.30up ₹49.80 (2.62%)BSE ₹1,951.25
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
52-week range of traded prices to 23 Oct 2026
₹1,251.60Low, 24 Oct 2025₹2,038.00High, 18 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
IPCA Laboratories board and management
21 filed, newest first.
Jun 2025
Mar 2025
Sep 2024
20 Sep · Management
May 2024
29 May · Management
Mar 2024
29 Mar · Management
Feb 2024
14 Feb · Management
Feb 2023
14 Feb · Management
Oct 2022
Mar 2019
29 Mar · Management
Aug 2017
May 2014
Mar 2013
25 Mar · Management
At the meeting of the Board of Directors of the Company held on March 23, 2013, Mr. Premchand Godha is re-appointed as the Managing Director of the Company for a further period of 5 years with effect from Aprll 01, 2013 subject to compliance with Sections 198, 269, 309, Schedule XIII and other applicable provisions, if any, of the Companies Act, 1956 and also subject to the approval of the Shareholders.
Apr 2012
Jan 2012
Jul 2011
Jul 2010
31 Jul · Management
At the meeting of the Board of Directors of the Company held on July 29, 2010, the Board has re-designated the incumbent Executive Director, Mr. A.K. Jain as the Joint Managing Director of the Company. The other terms and conditions of his appointment including the remuneration payable to him as earlier approved by the shareholders of the company, however, shall remain unchanged.
Jan 2010
21 Jan · Management
Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on January 21, 2010, Mr. Anand T. Kusre has been appointed as a Director of the Company. Mr. Kusre has been inducted as a member of the Audit Committee and Remuneration & Compensation Committee of the Board. Further the composition of the Board of Directors shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
11 Nov · Management
Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on November 11, 2008, Mr. Pranay Godha, son of Mr. Premchand Godha and who is currently President - APIs and Generics of the Company has been appointed as an Additional Director of the Company and designated as Wholetime Executive Director. The details of the composition of the Board of Directors of the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Nov · Management
Ipca Laboratories Ltd. has informed the Exchange that at the meeting of the Board of Directors of the Company held on October 31, 2008 the resignation of Mr. Thembalath Ramachandran from the Board of Directors of the Company, who has resigned his directorship due to his business/ professional pre-occupation, has been accepted. The revised composition of the Board of Directors of the Company now is as under : 1) Mr. R.S. Hugar : Chairman. 2) Mr. Premchand Godha : Managing Director. 3) Mr. M.R. Chandurkar : Director. 4) Mr. A.K. Jain : Executive Director. 5) Mr. Babulal Jain : Director. 6) Mr. V.A. Gore : Director. 7) Dr. V.V. Subba Rao : Director.